Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate
TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and lead pharmaceutical drug candidate ExoPTEN in optic nerve injury models. The studies were conducted in collaboration with Prof. Ygal Rotenstreich’s team at the Goldschleger Eye Institute at Sheba Medical Center. The new data supports the advancement of the Company’s optic nerve injury program into larger-animal studies, including a planned rabbit model, marking a key milestone toward potential human clinical evaluation.